Sage plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s after it failed to boost cognitive function in a Phase 2 ...

Sage Therapeutics plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s disease after the treatment failed to meet the main goal of improving cognitive ...

Alzheimer’s disease is a progressive neurodegenerative disorder that is characterized by declining mental abilities that affect memory, cognitive function, and personality. It is the most common cause ...

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by declining mental abilities that affect a person’s memory, cognition, and personality. It is the most common cause of ...

Alzheimer’s disease is a progressive neurodegenerative disorder and the most common cause of dementia. It most often emerges during a person’s mid-60s or older, although early-onset varieties exist.

Alzheimer’s disease is an irreversible, progressive neurological disorder associated with a gradual decline in mental and physical abilities. It is considered the most common form of dementia. The ...

In Alzheimer’s disease (AD), significant numbers of nerve cells in the brain die, affecting patients’ ability to remember things and to think clearly — resulting in confusion, behavioral changes and ...

While Alzheimer’s disease (AD) has no cure, five prescription medicines have been approved by the U.S. Food and Drug Administration (FDA) to treat disease symptoms that impact thinking and memory.

Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

There is a rapid growth in the number of people living with Alzheimer’s disease, and only around one in four people with the disease get diagnosed. It is estimated that there are approximately 44 ...